Business Wire

MA-KEEN-EYE/ULTIVUE

29.3.2022 20:40:03 CEST | Business Wire | Press release

Share
Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research

Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.

Ultivue develops unique solutions for use in mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples. This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.

Ultivue recognizes the need for dedicated and custom AI models to analyze the complexity of mIF data at scale and to provide improved turn-around times and consistent readouts across large cohorts “We are looking forward to accelerating data generation for biopharma customers from mIF kits by partnering with Keen Eye. We can jointly support more scalable workflows which will allow us to meet increasing demand in clinical trials.” said Florian Leiss, Ph.D. Vice President Digital Health Strategies at Ultivue.

Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis. Its proprietary models dedicated for spatial exploration of tumor microenvironment give access to reliable tissue segmentation, biomarker quantification, cell population profiling, and morphological discovery.

Thanks to Ultivue’s pre-optimized assays, the high accuracy achieved for every biomarker will drastically reduce errors during quantification steps as phenotypes combine several biomarkers. As Dr. Sylvain Berlemont, Keen Eye’s founder and CEO says, “We are thrilled to expand our application portfolio combined with best-in-class Ultivue mIF assays to biopharma companies and CROs. This partnership will undeniably support our customers to fully extend reproducibility and scalability throughout their clinical research.”.

About Keen Eye

Keen Eye is a health technology company based in Paris, aiming to bring AI into every research laboratory, CRO and pharmaceutical company, for the benefit of biologists, pathologists, and patients. Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms. Keen Eye strives to support the development of new therapies with better, faster, and accurate analytics. Learn more at keeneye.ai.

About Ultivue

Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vultr Expands European Footprint with 33rd Cloud Data Center Region in Milan, Italy19.5.2026 17:28:00 CEST | Press release

New region strengthens Vultr's commitment to affordable, high-performance cloud infrastructure and Europe's thriving open source and AI ecosystem Vultr, the world’s largest privately-held cloud infrastructure company, today announces the launch of its 33rd global cloud data center region in Milan, coinciding with AI Week 2026 at Fiera Milano Rho, where over 700 international speakers will gather for Europe's largest AI event. Vultr is a platinum sponsor and is also co-hosting the AI Agent Olympics Hackathon with over 1,000 participants. Milan becomes Vultr's ninth European cloud data center region, joining Amsterdam, Frankfurt, London, Madrid, Manchester, Paris, Stockholm, and Warsaw. This launch represents the company's latest expansion of a global network reaching 90% of the world's population within 2–40 milliseconds. Vultr’s cloud data center location will be delivering Vultr’s full-stack AI infrastructure, including Vultr’s flagship cloud compute offering, VX1, in addition to Vult

Global Millennial Capital Closes USD 100 Million IPO Opportunities Fund Focused on AI, Decentralized Financial Infrastructure, and Climate Technologies19.5.2026 17:16:00 CEST | Press release

Global Millennial Capital Ltd. (“GMCL”) today announced the final closing of its inaugural IPO Opportunities Fund at USD 100 million. Raised through a private placement with institutional and professional investors, the fund targets late-stage and special opportunities investments across mid-cap technology companies operating in high-growth sectors, including artificial intelligence, decentralized finance infrastructure, cybersecurity, digital infrastructure, enterprise software, and climate technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519513523/en/ Global Millennial Capital announces the successful final close of its USD 100 million IPO Opportunities Fund, reinforcing its commitment to investing in high-growth technology companies across artificial intelligence, digital infrastructure, cybersecurity, and next-generation financial systems. The fund is designed to capitalize on the increasing number of tech

Miro Takes Aim at the Gap Between AI Potential and Organizational Reality19.5.2026 16:00:00 CEST | Press release

At Canvas 26, Miro establishes its AI platform as the connective layer of the modern AI ecosystem — bringing together teams, agents, and the tools they already work in to turn individual AI productivity into organization-wide transformation Miro®, the AI Innovation Workspace for teams, has announced new innovations across its AI platform, reinforcing its position as the collaboration layer where people, context, and agents from every function converge to solve hard problems, make better decisions, and build the right thing faster. Major upgrades to Miro’s agentic AI tools — including Sidekicks and Flows — alongside new Connectors, help customers close the gap between individual AI productivity and organization-wide transformation. AI is reshaping the pace of work, but often teams are not realising the benefits. In many organizations, a gap has emerged between what individuals can now do and what companies can harness. The reason? Collaboration has fractured. Teams have moved from one m

Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 15:30:00 CEST | Press release

Roll-out at largest EU cancer center marks first Medi-Span NHS implementation Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer cen

Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 15:00:00 CEST | Press release

With Jit Acquisition, Torq Catapults Enterprise SOCs Into a New Realm of Detailed Contextual Investigations That Drive Precision Decision-Making Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye